Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19

Currently, there is a persisting dispute regarding the renin-angiotensin-aldosterone-system (RAAS) inhibitors' safety of use in COVID-19 pandemics. On one side, RAAS inhibitors appear to determine an overexpression ACE2, receptor SARS-CoV-2. Therefore, they could increase risk SARS-CoV-2 infection and its degree severity. other discontinuation leads cardiovascular decompensation has been discouraged by major medical societies. Also, large-cohort studies report beneficial or at least neutral effects for patients. Worldwide, millions patients receive treatment hypertension important comorbidities. In this context, knowledge exact effect these medications becomes crucial significance. This paper aims fill gap current presents putative mechanism which inhibitor administration's results can be explained better. beneficial, as counteract excessive detrimental activation classical angiotensin-converting enzyme (ACE) axis, decreasing angiotensin II levels. The blockers (ARBs) levels, while (ACEI) I levels; substrates will compete with ACE2 binding, viral infectivity. addition, following treatment, up-regulated cleave (angiotensin II), particularly 1-7 that possesses vasodilator, protective effects.